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A B S T R A C T
Up-regulation of intercellular adhesion molecule-1 (ICAM-1) and its soluble form are involved in the chronic
inflammation. For the first time, we demonstrated that resveratrol (RE), a natural polyphenol with antioxidant
and anti-inflammatory properties, reduces the increase of expression and release of ICAM-1, due to TNFα-in-
duced oxidative stress, in a myofibroblast cell line derived from human colonic (18Co cells). RE is scavenger of
radical oxygen species (ROS) and modulates signaling pathways in which Sirt-1 and NF-κB are involved.
Effectively, in TNFα-stimulated 18Co cells RE decreases ROS production and increases Sirt-1 expression and
activity, but it reduces TNFα-induced ICAM-1 up-regulation by a Sirt-1-independent mechanism, as demon-
strated by EX527 and Sirt-1 siRNA treatments. RE inhibits TNFα-induced activation of NF-κB by reducing both
ROS and the degradation of IκB-α, an endogenous inhibitor of NF-κB, with consequent decrease of NF-κB nuclear
translocation. This study also shows that NF-κB is not the only factor involved in the TNFα-induced ICAM-1 up-
regulation and confirms our previous evidence according to which TNFα increases ICAM-1 levels by redox- and
non-redox-regulated mechanisms. RE can represent good and useful support in therapies for intestinal in-
flammatory diseases in which TNFα plays a crucial role in the increase of adhesion molecule expression.
1. Introduction
Intercellular adhesion molecule-1 (ICAM-1)1, a glycoprotein ex-
pressed on the surface of various cell types, represents an important
regulator of inflammation contributing to the leukocyte infiltration into
inflammatory site by inducing adhesion and activation [1]. ICAM-1
expression is up-regulated by pro-inflammatory factors and/or oxida-
tive stress [2-5] in various inflammatory and immunological disorders
[6-9]. Moreover, ICAM-1 up-regulation is related to intestinal patho-
logical conditions such as inflammatory bowel disease (IBD) [10,11]. In
particular, IBD patients present an up-regulation of ICAM-1 expression
on membranes of intestinal epithelial and fibroblast cells, and an en-
hancement of soluble ICAM-1 (sICAM-1) form, probably deriving from
ICAM-1 shedding on the surface of intestinal cells, occurs in serum of
Crohn’s disease (CD) patients [11-14]. The increase of ICAM-1 and
sICAM-1 can be crucial in chronic inflammation and this contributes to
excessive infiltration of leukocytes to the inflammatory site [15] and
stimulates cytokine production [16,17]. We have previously reported
that tumor necrosis factor-alpha (TNFα), a crucial pro-inflammatory
mediator involved in IBD inflammatory processes [18], up-regulates
ICAM-1 expression and its release in a myofibroblast cell line derived
from human colonic mucosa, CCD-18Co (18Co) cells [5]. In these cells,
TNFα increases the production of radical oxygen species (ROS) that are
in part responsible for TNFα-induced ICAM-1 expression and release. In
fact, N-acetylcysteine (NAC), an antioxidant precursor of GSH synth-
esis, prevents the increase of expression and release of ICAM-1 due to
TNFα-induced oxidative stress [5]. 18Co cells show many properties of
intestinal subepithelial myofibroblasts (ISEMFs) that are involved in
different functions, including the mucosal repair and inflammatory
processes, both in healthy and ill intestine [19]. These cells play an
important role in the physiopathology of IBD by secreting pro-in-
flammatory mediators such as cytokines, chemokines,
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metalloproteinases and adhesion molecules [12,20-22]. In particular,
ISEMFs isolated from colonic mucosa of CD patients are characterized
by oxidative stress that induces the up-regulation of pro-inflammatory
mediators that in turn can cause an overproduction of ROS [23-27]. For
this, the effect of natural phytochemicals with antioxidant properties,
such as flavonoids and other polyphenols, in the modulation of in-
testinal inflammation has been investigated [28-30]. Resveratrol (RE)
(trans-3,5,4’-trihydroxy-stilbene), a polyphenol present in red wine,
some berries and peanuts, shows antioxidative and anti-inflammatory
functions in IBD [29]. In experimental models for chronic inflammatory
intestinal disease RE reduces neutrophil recruitment, TNFα production
and the activity of adhesion molecules [31,32]. Studies performed in
intestinal cells treated with lipopolysaccaride show that RE exerts its
role by decreasing cyclooxygenase-2 expression and inhibiting nuclear
factor-kappa B (NF-κB) activation [33,34]. Considering this and that a
therapeutic role for RE has been suggested in IBD [29], in this study we
investigated the effect of RE on TNFα-induced oxidative stress and on
consequent up-regulation of ICAM-1 expression and release in 18Co
cells. RE effect on NF-κB was also studied in TNFα-up-regulated ex-
pression of ICAM-1 by evaluating the involvement of sirtuin-1 (Sirt-1), a
deacetylase that regulates various biological anti-inflammatory pro-
cesses [35,36]. In fact, RE up-regulates activity and expression of Sirt-1
that is related also to down-regulation of NF-κB activity by deacety-
lating RelA/p65 subunit at Lysine 310 [37]. In fact, numerous prop-
erties of RE are due to Sirt-1-dependent mechanisms [38,39].
2. Materials and Methods
2.1. Cell culture and treatment
CCD-18Co (18Co) cells, obtained from American Type Culture
Collection (Manassas, VA), were used in our experiments with popu-
lation doubling level (PDL)= 27–36, given that the line begins to se-
nescence at about PDL=42. PDL was calculated using the equation
PDL=ln (CH/CS) x 1/ln2, in which CH is viable cell harvested number
and CS is cell seeded number. The substances used for cell culture and
treatments were purchased from Sigma-Aldrich, (St. Louis, Missouri,
USA). Cells were cultured at 37 °C in a 5% CO2 atmosphere in minimum
essential medium with 2mM glutamine and 1.5 g/l sodium bicarbo-
nate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and
10% fetal bovine serum. Culture media were supplemented with
72mg/l penicillin and 100mg/ml streptomycin. Confluent and 24-hour
serum-starved 18Co cells were pre-treated or not with various con-
centrations of RE (25–200 μM) or pyrrolidine dithiocarbamate (PDTC)
(1–50 μM) 1 h before and during the subsequent stimulation (2 or 24 h)
or not with 10 ng/ml TNFα. RE concentration range includes those used
in our previous study to detect the ability of RE to prevent oxidative
stress in these cells [40]. In other experiments, 20mM NAC was added
or not to cells during the last 16 h of starvation and during the sub-
sequent stimulation or not with 10 ng/ml TNFα as previously reported
[5]. In experiments with EX527, 10 and 20 μM of this compound were
added to 24-hrs serum-starved 18Co cells 1 h before pre-treatments and
subsequent TNFα-stimulations. 0.008 % DMSO (vehicle for RE and
EX527) was present in the respective RE- and/or EX527-untreated cells.
Cells were stimulated for 2 h with TNFα for detection of IκB-α levels
and NF-κB nuclear translocation, and for 24 h for detection of ICAM-1,
Sirt-1, NF-κBp65 (NF-κB) expression. To relate acetylation NF-κB p65 to
Sirt-1 expression and activation, acetylated NF-κB p65 (ac-NF-κB) levels
were detected after 24 h of TNFα-stimulation. Some treatments to de-
tect ICAM-1 expression were performed in cells transiently transfected
with 75 nM human Sirt-1 siRNA corresponding to two DNA target se-
quences of human Sirt-1 (5’-GUGUCAUGGUUCCUUUGCA[dT][dT]-3’;
5’-UGCAAAGGAACCAUGACAC[dT][dT]-3’) (Sigma-Aldrich), or
scrambled siRNA (Scr siRNA) (Universal Negative Control # 1, Sigma
Aldrich), using lipofectamine RNAiMAXTM (Invitrogen, Carlsbad, Cali-
fornia, USA) according to the manufacturer’s instructions. The ability of
siRNA to silence Sirt-1 expression levels in control cells was checked
24 h after transfection by Western blot analysis. The concentrations of
all compounds used did not reduce the viability according to Trypan
blue exclusion test.
2.2. Intracellular ROS production assay
The intracellular production of ROS was assayed, as previously
described [41], in 18Co cells seeded in 12-well plates, and treated as
described above. 30 min before the end of various treatments, 5 g/l 2’-
7’-dichlorodihydrofluorescein diacetate (H2DCF-DA) was added in
culture medium. After PBS washing, 18Co cells were lysed in 50mM
Tris/HCl pH 7.5, 1% Triton X100, 150mM NaCl, 100mM NaF, 2mM
EGTA (RIPA buffer) and fluorescence intensity was detected using a
Fluoroskan AscentFL microplate reader (Thermo Fisher Scientific,
Waltham, Massachusetts, USA) at 485 nm excitation and 518 nm
emission wavelengths. Data have been normalized on total protein
content and values were expressed as percentage of ROS production
measured in untreated and unstimulated cells (control).
2.3. ICAM-1 and sICAM-1 assay
sICAM-1 release and intracellular ICAM-1 levels were measured in
cell lysates and in the respective culture media, using Human ICAM-1
ELISA kit (Uscn Life Sciences Inc., Wuhan, Hubei, PRC) according to the
manufacturer’s instructions. 18Co cells were seeded in 12-well plates
and treated as described above. For cell lysates preparation, cells were
detached with trypsin and collected by centrifugation at 130 x g for
10min. Cells, washed three times in cold phosphate buffer saline (PBS),
were suspended in PBS and ultrasonicated for 4 times. Subsequently,
cell lysates were centrifuged at 1500 x g for 10min at 4 °C to remove
cellular debris and ICAM-1 assay was performed in the supernatants.
Data have been normalized on total protein content and sICAM-1 and
ICAM-1 levels were expressed as percent of the respective levels mea-
sured in control.
2.4. Sirt-1 expression assay
Sirt-1 expression was measured in 18Co cells, seeded in 12-well
plates and treated as described above, by using Human SIRT1 ELISA kit
(Abcam, Cambridge U.K.). Briefly, cell extracts were obtained in cells
previously solubilized in Cell Extraction Buffer and centrifugated at
18,000 x g for 20min at 4 °C according to the manufacturer’s instruc-
tions. Data have been normalized on total protein content and Sirt-1
expression was expressed as percent of the respective levels measured
in control.
2.5. Western blotting
Ac-NF-κB, NF-κB and IκB-α levels were analysed by Western blot in
18Co cells seeded in p-60 plates treated and stimulated or not as de-
scribed above. Cells were lysed in ice-cold RIPA buffer containing
phosphatase and protease inhibitor cocktails, purchased from Sigma
(St. Louis, MO) and, after 15 min on ice, were centrifuged at 11,600 x g
for 10min and supernatants were subjected to Western blot analysis.
Preparation of nuclear extracts for detection of NF-κB translocation was
performed as described by Bai et al. [42]. Protein concentrations were
determined by the bicinchoninic acid solution (BCA) protein reagent
assay (Pierce) [43] using bovine serum albumin as standard (Sigma, St.
Louis, MO). Equal amount of total proteins (30–35 μg) were loaded in
each line and were subjected to sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS/PAGE) on 10 % (w/v) gel and
electrotransferred to PVDF membrane (GE Healthcare, Chicago, IL) that
was probed with specific antibodies anti-acetyl-NF-κBp65/Lys310 or
anti-NF-κBp65 or anti-IκB-α (Cell Signalling Technology Inc., Danvers,
MA) or anti- β-actin or anti-GAPDH or anti-Histone H3 (Santa Cruz
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Biotechnology, Inc.). Secondary antibodies conjugated to horseradish
peroxidase were used to detect antigen-antibody complexes with a
chemiluminescence reagent kit (GE Healthcare, Chicago, IL). Amer-
sham Imager A600 (GE Healthcare, Chicago, IL) was used for capture of
high resolution digital images of the bands whereas densitometric
analysis was performed using ImageJ Software (National Institutes of
Health, USA). β-actin or GAPDH or Histone H3 bands were used for
normalization in densitometric analysis and values were expressed as
percentage variations relative to controls.
2.6. Statistical analysis
All experiments were carried out three or four times. Data are ex-
pressed as the mean ± SEM and statistical significance of the differ-
ences was determined by using one-way ANOVA analysis with
Bonferroni’s multiple comparison test, using the GraphPad Prism
Software. p≤ 0.05 was considered statistically significant.
3. Results
3.1. Effect of RE on TNFα-induced intracellular ROS production.
Initially, it has been investigated the effect of RE at various con-
centrations (25–200 μM) on TNFα-induced ROS production in 18Co
cells. Fig. 1 shows that the significant increase of ROS, detected in
10 ng/ml TNFα-stimulated cells, was not prevented by pre-treatment
with 25 μM RE. Differently, all other concentrations of RE down-regu-
lated TNFα-induced ROS production. In fact, 50 μM RE restored ROS to
control values, whereas 100 μM and 200 μM RE decreased significantly
ROS levels at values lower than those of control (Fig. 1).
3.2. Effect of RE on TNFα-induced ICAM-1 expression and sICAM-1
release.
Detection of ICAM-1 expression and sICAM-1 release were per-
formed in 18Co cells by ELISA kit in cell lysates and in culture media,
respectively. Fig. 2 A, B shows that ICAM-1 and sICAM-1 were up-
regulated by 10 ng/ml TNFα and that the pre-treatment with 25 μM RE
did not affect this according to ROS levels. On the contrary, pre-
treatment with 50-200 μM RE decreased ICAM1-expression and release
in the same way and significantly as compared to TNFα-treated cells,
indicating the lack of a dose-response relationship. However, at these
concentrations of RE ICAM-1 expression levels were not similar or
lower than control values, differently to that occurred for ROS pro-
duction and sICAM-1 release. In fact, 50–200 μM RE restored TNFα-
induced sICAM-1 levels to control values (Fig. 2 B). Considering that RE
is a strong activator of Sirt-1 [44], we evaluated the effect of RE on
ICAM-1 expression and release in the presence of 10 μM EX527, a Sirt-1
inhibitor [45]. This inhibitor did not affect ICAM-1 expression and
sICAM-1 release in all conditions used (Fig. 2A and B).
3.3. Effect of RE on Sirt-1 expression and activity in TNFα-stimulated cells.
Subsequently, expression and activity of Sirt-1 in 18Co cells sti-
mulated with TNFα and pre-treated or not with various concentrations
of RE, were detected. Sirt-1 activity was measured by evaluating the
levels of acetylated-NF-κB subunit Rel/p65 at lysine 310 (ac-NF-κB).
Fig. 3A and B shows that TNFα did not induce an increase of the ex-
pression and activity of Sirt-1 in non-pre-treated or in 50 μM RE pre-
treated cells, as compared to control cells. Differently, pre-treatment
with 100 and 200 μM RE induced a similar and significant increase in
Sirt-1 expression with consequent remarkable decrease in ac-NF-κB
Fig. 1. Intracellular ROS production in 18Co cells pre-treated or not with RE
and stimulated with TNFα. Starved 18Co cells, pre-treated or not with various
concentrations of RE (25–200 μM), were stimulated or not for 24 h with 10 ng/
ml TNFα, as reported in Materials and Methods. The intracellular ROS pro-
duction was detected by measuring the fluorescence intensity of the in-
tracellular oxidation-sensitive probe H2DCFDA. The values, normalized on total
protein content and expressed as percentage of untreated and unstimulated
cells (control, C), are the mean ± SEM of four experiments repeated in tri-
plicate. *p ≤ 0.001; **p≤ 0.01 compared to C cells; ○p≤ 0.001 compared to
RE untreated and TNFα stimulated cells; Δp≤ 0.01 compared to 50 μM RE pre-
treated and TNFα stimulated cells.
Fig. 2. ICAM-1 expression and sICAM-1 release with or without EX527 in 18Co
cells pre-treated or not with RE and stimulated with TNFα. Starved 18Co cells,
pre-treated or not with various concentrations of RE (25–200 μM), were sti-
mulated or not for 24 h with 10 ng/ml TNFα in the presence or the absence of
10 μM EX527, as reported in Materials and Methods. Expression of ICAM-1
levels (A) and sICAM-1 levels (B) were assayed by ELISA kit in cell lysates and
in culture media, respectively. The values, expressed as percentage of untreated
and unstimulated cells (control, C), are the mean ± SEM of four experiments
repeated in triplicate.*p ≤ 0.001; **p≤ 0.05 compared to C cells; ○p≤ 0.001;
○○p≤ 0.05 compared to RE untreated and TNFα stimulated cells.
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levels, in TNFα-stimulated cells. On the contrary, NAC, an antioxidant
that reduces TNFα-up-regulated ICAM-1 expression similarly to RE [5],
did not affect expression and activity of Sirt-1 in 18Co cells stimulated
with TNFα (Fig. 3A and B). To verify that EX527 at concentration used
for the detection of ICAM-1 (Fig. 2) was effectively able to inhibit Sirt-1,
we measured ac-NF-κB levels in the absence or in the presence of this
inhibitor. Fig. 3C shows that the highest concentration used of EX527
did not affect ac-NF-κB levels in TNFα-stimulated cells. On the contrary,
10 and 20 μM EX527 significantly increased levels of ac-NF-κB in
100 μM RE pre-treated and TNFα-stimulated cells, as compared to RE-
pretreated cells without inhibitor. Moreover, EX527 restored ac-NF-κB
levels to those detected in TNFα-stimulated cells. The levels of NF-κB
expression did not change and were similar in all experimental
conditions (Fig. 3B and C). Therefore, even if RE is able to induce in
these cells expression and activity of Sirt-1, this deacetylase does not
seem to be involved in the effect of RE on TNFα-induced ICAM-1 ex-
pression and release.
3.4. Effect of RE on IκB-α degradation in TNFα-stimulated cells.
Under physiological conditions NF-κB is inactivated by interaction
with its endogenous inhibitor, IκB-α protein, that when degraded in-
fluences subsequent nuclear translocation of NF-κB subunits [46]. For
this, the role of RE in TNFα-treated 18Co cells on IκB-α degradation and
nuclear translocation of NF-κB were studied. Fig. 4A shows that the IκB-
α protein was significantly degraded in 18Co cells stimulated with
10 ng/ml TNFα, as compared to control cells. IκB-α degradation was
not affected by pre-treatment with RE 25 μM in agreement with its ef-
fect on ROS production and ICAM-1 levels. All other concentrations
used of RE were able to inhibit TNFα-induced IκB-α degradation by
restoring the levels of this protein to those of control, similarly to
20mM NAC and 50 μM PDTC, a specific inhibitor of NF-κB [47]. IκB-α
levels were not reversed by EX527 treatment (Fig. 4A) and were related
to nuclear NF-κB levels in 18Co cells pretreated or not with RE and
stimulated with TNFα (Fig. 4B). In fact, Fig. 4B shows that TNFα in-
duced an increase of nuclear NF-κB levels that were restored to control
levels in the presence of 50-200 μM RE but not with 25 μM RE. The
influence of NAC and PDTC on ICAM-1 expression levels was compared
to 100 μM RE in TNFα-stimulated cells transfected or not with specific
Sirt-1 siRNA that induced a decrease in Sirt-1 expression in control cells
after 24 h of transfection (Fig. 4C). Fig. 4D shows that NAC and 50 μM
PDTC had a similar effect to 100 μM RE and did not restore ICAM-1
levels to those of control. siRNA of Sirt-1 did not reverse neither the
effect of RE nor that of NAC or PDTC (Fig. 4C), confirming the non-
involvement of Sirt-1 in the role of RE on TNFα-induced ICAM-1 ex-
pression. 10 μM PDTC was not able to reduce ICAM-1 expression
(Fig. 4D) and concentrations of this compound lower than 50 μM did
not affect IκB-α degradation detected in TNFα-stimulated 18 Co cells
(Fig. 4E).
4. Discussion
RE, a natural polyphenolic compound involved in the treatment of
various pathologies, possesses many pharmacological activities, in-
cluding antitumor, anti-inflammatory, anti-aging, antioxidant and anti-
diabetic effects [48]. The beneficial properties of RE are due to its
ability to neutralize ROS or to regulate signaling pathways in which
Sirt-1 and NF-κB are involved [49]. For the first time, this study shows
that RE is able to reduce the oxidative stress and to down-regulate
ICAM-1 expression and release by a Sirt-1 independent mechanism in
TNFα-stimulated 18Co cells. In particular, at the lowest concentration
(25 μM) RE does not influence ROS production and ICAM-1 expression
and release, differently to that occurs with the other concentrations of
RE used. In fact, at these concentrations, RE is not able to restore ICAM-
1 expression to control values differently to that occurs for sICAM-1,
even if RE totally prevents TNFα-induced ROS levels. It is possible that
RE effect on sICAM-1 values can be both due to diminished expression
of ICAM-1 and to the consequent inhibition of ROS-activated proteases
involved in ICAM-1 shedding. The protective role of RE on TNFα-in-
duced of oxidative stress is in accordance with its preventive effect on
oxidative stress induced by buthionine sulfoximine or starvation in
18Co or in MLO-Y4 cells, respectively [40]. Moreover, RE prevents
oxidative stress caused by high levels of glucose in smooth cells [50]
and TNFα-induced ROS production in HUVEC cells [51]. Sirt-1, be-
longing to NAD+-dependent deacetylase family, plays a crucial role in
the regulation of various biological and metabolic activities by mod-
ulating transcriptional factors such as p53, NF-κB and forkead box 0,
with consequent change of gene expression responsible for the protec-
tion against apoptosis, oxidative stress and aging [52]. RE is an
Fig. 3. Ac-NF-κB, total NF-κB levels and Sirt-1 expression in 18Co cells pre-
treated or not with RE and stimulated with TNFα. Starved 18Co cells, pre-
treated or not with various concentrations of RE (25–200 μM), were stimulated
or not for 24 h with 10 ng/ml TNFα, as reported in Materials and Methods. Sirt-
1 expression was assayed by ELISA kit in cell lysates (A). The values, expressed
as percentage of untreated and unstimulated cells (control, C), are the
mean ± SEM of four experiments repeated in triplicate. Ac-NF-κB and NF-κB
levels in the absence (B) or in the presence of 10 or 20 μM EX527 (C) were
detected in cells lysates by Western blot analysis using anti-acetyl-NF-κBp65/
Lys310 or anti-NF-κBp65. Blots are representative of three experiments and the
normalized values with β-actin or GAPDH bands are reported in the bottom.
The values are expressed as percentage ± SEM relative to those obtained in
untreated and unstimulated cells (control, C) for B, or to those obtained in
EX527-untreated and TNFα-stimulated cells, for C. *p≤ 0.001; **p≤ 0.01
compared to C cells; ○p≤ 0.001; ○○p≤ 0.01 compared to untreated and TNFα
stimulated cells; Δp≤ 0.01 compared to 100 μM RE pre-treated and TNFα sti-
mulated cells.
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activator of Sirt-1 and often exhibits its anti-aging, anti-inflammatory
and antioxidant properties through the up-regulation of this deacetylase
[53-55], as it occurs in the mitigation of TNFα-induced inflammation in
fibroblasts and in the attenuation of triglyceride in adipocytes [56,57].
The up-regulation of adhesion molecules that occurs in pathological
conditions can be inhibited by RE. In fact, it is able to prevent the
(caption on next page)
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expression of adhesion molecules induced by pro-inflammatory med-
iators in endothelial cells [48,55,58-60], and to exert its anti-in-
flammatory effect by suppressing ICAM-1 and VCAM-1 levels in colon
and serum in a rat model of ulcerative colitis [32]. The mechanism by
which RE inhibits adhesion molecules expression can be mediated by
Sirt-1 as it happens in lipopolisaccaride-stimulated HUVEC cells and in
obese septic mice [55]. Other data show that RE reduces ICAM-1 ex-
pression and leukocyte adhesion in the retina of mice with ocular in-
flammation by dual mechanisms involving the antioxidant properties of
RE and its ability to activate Sirt-1 [61]. In the present study, high RE
concentrations in TNFα-stimulated 18Co cells up-regulate the expres-
sion of Sirt-1 and induce a significant decrease in the deacetylation of
NF-κB, reverted by Sirt-1 inhibitor, EX527, without interfereing on total
NF-κB expression levels. However, Sirt-1 is not involved in the capacity
of RE to decrease ICAM-1 levels as demonstrated by experiments per-
formed in the presence of EX527 and in cells transfected with specific
Sirt-1 siRNA. Indeed, this is evident also considering that 50 μM RE
treatment reduces TNFα-induced ICAM-1 expression and ROS levels but
does not increase Sirt-1 expression and activation. It seems that, in
these experimental conditions, RE affects ICAM-1 levels only by its
antioxidant role similarly to that previously obtained with NAC [5]
that, on the contrary, does not affect expression and activity of Sirt-1.
Then, we suggest that RE reduces ICAM-1 expression and release by
decreasing TNFα-induced oxidative stress in 18Co. Effectively, TNFα
does not affect Sirt-1 expression and does not enhance NF-κB activity
through its acetylation in our experimental conditions. This can explain
why RE can act through a Sirt-1 independent manner, even if it reduces
the levels of ac-NF-κB below those of control. In 18Co cells, TNFα ac-
tivates NF-κB by inducing ROS and decreasing IκB-α levels, an en-
dogenous inhibitor of NF-κB. TNFα stimulates NF-κB activity by a sig-
naling pathway that involves proteins of complex I [62], and oxidative
stress can affect NF-κB activity [63]; in both cases, an increased de-
gradation of IκB-α occurs. We demonstrated that in 18Co stimulated
with TNFα, RE inhibits ROS production and IκB-α degradation with
consequent decrease of NF-κB nuclear translocation and ICAM-1 ex-
pression. Indeed, RE blocks NF-κB activation in various cell types and
this can occur also by inhibiting mechanisms involved in IκB-α de-
gradation [64]. In 18Co cells, we suggest that TNFα-induced oxidative
stress activates NF-κB considering that all RE concentrations, except for
25 μM, are able to restore IκB-α to control levels also in the presence of
EX527. These data confirm that, in our experimental conditions, RE
does not involve Sirt-1 in the inhibition of NF-κB, considering also that
50 μM RE inhibits NF-κB and this is in agreement with ROS levels and
ICAM-1 expression but not with Sirt-1 expression level. Indeed, in
murine macrophages, RE also regulates the inflammatory responses by
decreasing and increasing ac-NF-κB and IκB-α levels, respectively,
without affecting total NF-κB levels [65]. However, these effects in
macrophages are reversed by EX527 treatment [65] differently to that
occurs in 18Co cells, in which EX527 reverses the effect of RE on NF-κB
acetylation but not on IκB-α and ICAM-1 levels. 50 μM PDTC, with
antioxidant properties often related to its inhibitory role on NF-κB
[66,67], and NAC restore IκB-α values, but not ICAM-1 levels to control
values in TNFα-stimulated 18Co. EX527 treatment or Sirt-1 siRNA
transfection did not reverse these effects, similarly to that occurs with
RE. Indeed, to investigate and clarify RE role and/or Sirt-1 involvement
on NF-κB, PDTC is frequently used [66,68-70]. In our study, the be-
havior of RE is similar to that of PDTC and NAC, clarifying that effec-
tively RE suppresses TNFα-induced NF-κB activation and ICAM-1 ex-
pression without Sirt-1 involvement. Moreover, PDTC at concentration
lower than 50 μM did not affect IκB-α and ICAM-1 levels similarly to
that occurs with 25 μM RE. These data altogether indicate that the ac-
tivation of NF-κB is involved effectively in TNFα-up-regulated ICAM-1
expression but the activation of this transcriptional factor is not the
only mechanism implicated. Moreover, they confirm that RE regulates
TNFα-induced NF-κB activation and ICAM-1 expression by attenuating
ROS production in a Sirt-1-independent manner. RE reduces totally
TNFα-induced ROS production but not ICAM-1 expression, confirming
our previous data that show the partial involvement of TNFα-induced
oxidative stress in the increase of ICAM-1 expression [5]. Then, it is
strengthened the hypothesis that the enhancement of ICAM-1 expres-
sion in TNFα-stimulated myofibroblasts is due to redox-dependent and
-independent mechanisms, and RE, acting as antioxidant, is able to
reduce the increase of ICAM-1 expression due to redox-dependent
mechanism of TNFα. The anti-inflammatory role of RE in intestinal cells
was studied in CaCo-2 cells, in SW480 human colon adenocarcinoma
cells [33,34], and in animals. RE attenuates inflammatory mediators
secretion and molecule adhesion levels in colon and serum [31,32] and,
by reducing the expression of adhesion molecules in intestinal myofi-
broblasts, RE also decreases sICAM-1 levels. This effect can down-reg-
ulate development of cancer that can be consequent to the chronic in-
flammation [71]. In fact, an increase of ICAM-1 and its soluble form can
be involved in the tumor differentiation and in the development of
metastasis, respectively [72,73].
5. Conclusions
For the first time, this study shows that, RE reduces TNFα up-
regulated ICAM-1 expression and release through a Sirt-1 independent
and redox-regulated mechanism in 18Co cells (Fig. 5). In fact, RE in-
creases Sirt-1 expression and activity in 18Co, but these effects are not
involved in RE regulation of TNFα-induced NF-κB activation partially
involved in the increase of ICAM-1. RE inhibits IκB-α degradation and
Fig. 4. IκB-α levels, nuclear NF-κB and ICAM-1 expression in 18Co cells pre-treated or not with RE, NAC or PDTC and stimulated with TNFα. Starved 18Co cells, pre-
treated or not with various concentrations of RE (25–200 μM) or PDTC (1–50 μM) or 20 mM NAC, were stimulated or not for 2 h with 10 ng/ml TNFα, as reported in
Materials and Methods. IκB-α (A) and nuclear NF-κBp65 (B) levels were detected in cell lysates and in nuclear extracts, respectively, by Western blot analysis using
anti-IκB-α or anti-NF-κBp65. Blots are representative of three experiments and the normalized values with β-actin or Histone H3 bands are reported in the bottom.
The values are the mean percentage ± SEM relative to those obtained in the untreated and unstimulated cells (control, C). Expression of ICAM-1 levels (D) by ELISA
kit were assayed in lysates of cells transfected with Sirt-1 siRNA or Scr siRNA, pre-treated as reported above and stimulated for 24 h with 10 ng/ml TNFα. The values,
expressed as percentage of respective untreated and unstimulated cells (control, C), are the mean ± SEM of four experiments repeated in triplicate. Sirt-1 levels (C)
were detected in lysates of cells transfected or not with Sirt-1 siRNA or Scr siRNA by Western blot analysis using anti-Sirt-1.*p ≤ 0.01; **p≤ 0.05 compared to C
cells; ○p≤ 0.05 compared to untreated and TNFα stimulated cells; Δp≤ 0.01; ΔΔp≤ 0.05 compared to TNFα stimulated cells or 25 μM RE pre-treated and TNFα
stimulated cells.
Fig. 5. Schematic representation of mechanism by which RE down-regulates
TNFα-induced oxidative stress and ICAM-1 expression in 18Co cells. TNFα in-
duces ROS production that activates IκB-α degradation and NF-κB pathway
signalling. This mechanism, in part involved in the increase of ICAM-1 ex-
pression, is inhibited by RE in a Sirt-1-independent manner.
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NF-κB nuclear translocation by reducing ROS production. The results
suggest also that NF-κB pathway is not the only mechanism involved in
TNFα-induced ICAM-1 up-regulation, and they supports our previous
hypothesis according to which TNFα increases ICAM-1 expression by
redox and other non-redox regulated mechanisms. Moreover, RE is ef-
ficient in ICAM-1 down-regulation in 18Co stimulated with TNFα at
lower concentrations than those used for other antioxidants, such as
NAC. For this, we speculate that RE, being present in food and natural
supplements, may be useful in supporting the anti-inflammatory and
anti-TNFα therapies used in intestinal inflammatory diseases, such as
IBD, in which an increased expression of adhesion molecules due to
TNFα occurs.
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